Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

@inproceedings{Turpie2012RationaleAD,
  title={Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery},
  author={Alexander G. G. Turpie and Andr{\'e} Michael Schmidt and Reinhold Kreutz and Michael Rud Lassen and Waheed Jamal and Lorenzo G Mantovani and Sylvia K Haas},
  booktitle={Vascular health and risk management},
  year={2012}
}
Venous thromboembolism is a frequent and potentially life-threatening complication of orthopedic surgery. Rivaroxaban is an oral direct factor Xa inhibitor, which was shown to be effective for the prevention of venous thromboembolism after elective hip and knee arthroplasty in the RECORD study program. Rivaroxaban has the potential to overcome the limitations of the current standards of care in the prevention of venous thromboembolism. XAMOS (Xarelto(®) in the prophylaxis of post-surgical… CONTINUE READING